COMMUNIQUÉS West-GlobeNewswire

SelectMDx Outperforms PCA3 Stratifying Men for mpMRI
11/09/2017
Test Reduces Unnecessary Invasive Procedures NEWS RELEASE IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, September 11, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced results from a retrospective study published [...]
SelectMDx plus performant que PCA3 pour sélectionner les hommes devant passer une IRM-mp
11/09/2017
Le test limite les procédures invasives inutiles COMMUNIQUÉ DE PRESSE IRVINE, CA, et HERSTAL, BELGIQUE - 07:00 CEST, 11 septembre, 2017 - MDxHealth SA (Euronext : MDXH.BR) a annoncé les résultats d'une étude [...]
INNATE PHARMA : New preclinical data further strengthen the rationale of IPH5401 and monalizumab
11/09/2017
ICI conference 2017: NEW PRECLINICAL DATA further strengthen the rationale of IPH5401 AND MONALIZUMAB for cancer treatments and in combination with anti-PD-1/PD-L1 IPH5401, an anti-C5aR antibody, potentially reverses [...]
INNATE PHARMA: nouvelles données précliniques renforçant le rationnel d'IPH5401 et monalizumab
11/09/2017
ConfÉrence ICI 2017 : NOUVELLES donnÉes prÉcliniques RENFORcant le rationnel d'iph5401 et monalizumab dans le traitement du cancer et en combinaison avec des anti-PD-1/PD-L1 En inversant l'immunosuppression dans le [...]
First Patients Enrolled in UK's Early Access to Medicines Scheme for Santhera's Raxone® in Duchenne Muscular Dystrophy (DMD)
11/09/2017
Liestal, Switzerland, September 11, 2017 - Santhera Pharmaceuticals (SIX: SANN) announces enrollment of first DMD patients with respiratory function decline not taking glucocorticoids into UK's Early Access to Medicines [...]
Targovax ASA: Three posters presented at ESMO conference
11/09/2017
Oslo, Norway, 11 September 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces that three posters [...]
Sanofi, Regeneron: Dupilumab Hits Main Objectives in Late-Stage Asthma Trial
11/09/2017
Sanofi and Regeneron Announce Positive Dupilumab Topline Results From Phase 3 Trial in Uncontrolled Persistent Asthma - Investigational dupilumab reduced severe asthma attacks and improved lung function - Paris, France [...]
Sanofi et Regeneron annoncent les premiers résultats positifs d'une étude de phase 3 consacrée au dupilumab dans le traitement de l'asthme persistant non contrôlé
11/09/2017
Sanofi et Regeneron annoncent les premiers résultats positifs d'une étude de phase 3 consacrée au dupilumab dans le traitement de l'asthme persistant non contrôlé - L'agent expérimental dupilumab a permis de réduire les [...]
Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma
11/09/2017
The three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, compared to 39% with placebo[1] Consistent improvement in RFS observed across all pre-specified subgroups, including [...]
Novartis presents new data at EURETINA 2017 confirming Lucentis® efficacy and durability vs aflibercept
09/09/2017
Interim results of the head-to-head RIVAL study confirm strong efficacy and comparable durability versus aflibercept in patients with nAMD Five-year results from the Lucentis LUMINOUS study, the largest ever in retinal [...]
L'Association internationale pour l'étude du cancer du poumon annonce des sélections de rapports pour la 18e Conférence mondiale sur le cancer du poumon
08/09/2017
Des travaux de recherche révolutionnaires mettront en lumière les progrès les plus récents dans l'étude du cancer du poumon DENVER, 2017-09-08 (GLOBE NEWSWIRE) -- L'Association internationale pour l'étude du cancer du [...]
LifeVantage Corporation élargit sa présence mondiale avec une expansion en Allemagne
08/09/2017
Les produits disponibles en Allemagne incluent le Synergizer Nrf2 Protandim® et TrueScience®, la crème antivieillissement pour les soins de la peau de la société SALT LAKE CITY, le 8 septembre 2017 (GLOBE NEWSWIRE) - [...]
PCI Biotech: Capital increase registered and listing of new shares
08/09/2017
Oslo, 8 September 2017 - Reference is made to the stock exchange notice of 5 September 2017 by PCI Biotech Holding ASA (the "Company") in respect of the issuance of 86,500 new shares following exercise of employee share [...]
Information from Infant Bacterial Therapeutics Capital Markets Day 2017
08/09/2017
Infant Bacterial Therapeutics has today, September 8, 2017, hosted a Capital Markets Day for investors, financial analysts and media in Stockholm. The purpose of the Capital Markets Day was to present Infant Bacterial [...]
Inivata: Inivata Announces Appointment of Dr Jamie Platt as Chief Operations Officer
08/09/2017
Inivata Announces Appointment of Dr Jamie Platt as Chief Operations Officer Research Triangle Park, NC and Cambridge, UK, September 8, 2017 -- Inivata , a global clinical cancer genomics company utilizing an industry- [...]
Medtronic Announces Japanese Regulatory Approval for the IN.PACT(TM) Admiral(TM) Drug-Coated Balloon
08/09/2017
Clinically-Proven, Durable, Consistent, and Safe Market-Leading DCB Poised to Improve Outcomes for PAD Patients in Japan DUBLIN - September 8, 2017 - Medtronic plc (NYSE: MDT) today announced that the IN.PACT(TM)Admiral [...]
Nicox : Informations financières et point des activités du premier semestre 2017
08/09/2017
Communiqué de presse Nicox : Informations financières et point des activités du premier semestre 2017 Approbation de la demande d'autorisation de mise sur le marché ( New Drug Application , NDA) de ZERVIATE TM (solution [...]
Nicox first half 2017 business and financial update
08/09/2017
Press Release Nicox first half 2017 business and financial update ZERVIATE TM (cetirizine ophthalmic solution), 0.24% New Drug Application (NDA) approved Investigational New Drug (IND) submissions for NCX 470 for IOP [...]
Sanofi, Regeneron: Cemiplimab Receives FDA Breakthrough Designation for Advanced Cutaneous Squamous Cell Carcinoma
08/09/2017
Sanofi and Regeneron Announce That Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma Paris, France and Tarrytown, New York - September 8, 2017 - [...]

Pages